Product
Autologous, humanized anti-CD19 CAR T cell therapy
1 clinical trial
2 indications
Indication
B-cell Acute Lymphoblastic LeukemiaIndication
B Lymphoblastic LymphomaClinical trial
Use of Autologous Anti-CD22 CAR T Cells (CART22-65s) Co-administered With Humanized Anti-CD19 CAR T Cells (huCART19) in Children and Young Adults With Relapsed or Refractory B-ALLStatus: Recruiting, Estimated PCD: 2027-01-15